MA29810B1 - 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques - Google Patents
4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiquesInfo
- Publication number
- MA29810B1 MA29810B1 MA30788A MA30788A MA29810B1 MA 29810 B1 MA29810 B1 MA 29810B1 MA 30788 A MA30788 A MA 30788A MA 30788 A MA30788 A MA 30788A MA 29810 B1 MA29810 B1 MA 29810B1
- Authority
- MA
- Morocco
- Prior art keywords
- thiadiazol
- oxy
- processes
- preparation
- benzenesulfonamides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE LES 4-OXY-N-[1,3,4]-THIADIAZOL-2-YL-BENZÈNE SULFONAMIDES AINSI QUE LEURS SELS PHYSIOLOGIQUEMENT ACCEPTABLES ET LEURS DÉRIVÉS PHYSIOLOGIQUEMENT FONCTIONNELS PRÉSENTANT UNE ACTIVITÉ AGONISTE VIS-À-VIS DE PPARALPHA, PPARDELTA ET PPARGAMMA. L¿INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I), LES RADICAUX ÉTANT TELS QUE DÉFINIS, AINSI QUE LEURS SELS PHYSIOLOGIQUEMENT ACCEPTABLES ET DES PROCÉDÉS POUR LEUR PRÉPARATION. LES COMPOSÉS CONVIENNENT POUR LE TRAITEMENT ET/OU LA PRÉVENTION DES PATHOLOGIES LIÉES AU MÉTABOLISME DES ACIDES GRAS ET À L¿UTILISATION DU GLUCOSE, AINSI QUE DES PATHOLOGIES LIÉES À LA RÉSISTANCE À L¿INSULINE ET À LA DÉMYÉLINISATION ET D¿AUTRES MALADIES NEURODÉGÉNÉRATIVES DU SYSTÈME NERVEUX CENTRAL ET PÉRIPHÉRIQUE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05021786 | 2005-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29810B1 true MA29810B1 (fr) | 2008-09-01 |
Family
ID=35455941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30788A MA29810B1 (fr) | 2005-10-06 | 2008-03-31 | 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques |
Country Status (15)
Country | Link |
---|---|
US (1) | US7910612B2 (fr) |
EP (1) | EP1937658A1 (fr) |
JP (1) | JP2009510144A (fr) |
KR (1) | KR20080053931A (fr) |
CN (1) | CN101277940A (fr) |
AR (1) | AR056121A1 (fr) |
AU (1) | AU2006299085A1 (fr) |
CA (1) | CA2624726A1 (fr) |
IL (1) | IL190460A0 (fr) |
MA (1) | MA29810B1 (fr) |
NO (1) | NO20081682L (fr) |
RU (1) | RU2008113210A (fr) |
TW (1) | TW200804324A (fr) |
WO (1) | WO2007039171A1 (fr) |
ZA (1) | ZA200801988B (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE549332T1 (de) | 2007-12-26 | 2012-03-15 | Sanofi Sa | Zyklische pyridyl-n-(1,3,4)-thiadiazol-2-yl- benzol-sulfonamide, verfahren für ihre herstellung und anwendung als pharmaka |
BRPI1006128A2 (pt) | 2009-01-12 | 2016-11-01 | Cagen Inc | derivados de sulfonamida |
GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
US9145407B2 (en) | 2010-07-09 | 2015-09-29 | Pfizer Limited | Sulfonamide compounds |
WO2012122368A1 (fr) * | 2011-03-08 | 2012-09-13 | The Regents Of The University Of California | Composés de liaison à la désoxycytidine kinase |
CN109526219B (zh) | 2016-05-20 | 2021-03-12 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
WO2017202376A1 (fr) * | 2016-05-26 | 2017-11-30 | 南京明德新药研发股份有限公司 | Dérivé de sulfamide |
BR112019011121A2 (pt) | 2016-12-09 | 2019-10-01 | Xenon Pharmaceuticals Inc | compostos de benzenossulfonamida e seu uso como agentes terapêuticos |
WO2019152955A1 (fr) | 2018-02-02 | 2019-08-08 | Steven Albert Everett | Conjugués de médicaments à petites molécules de monophosphate de gemcitabine |
CN112262142B (zh) | 2018-06-13 | 2023-11-14 | 泽农医药公司 | 苯磺酰胺化合物及其作为治疗剂的用途 |
CR20210099A (es) | 2018-08-31 | 2021-06-24 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapèuticos |
US10752623B2 (en) | 2018-08-31 | 2020-08-25 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
KR20230129384A (ko) | 2020-11-02 | 2023-09-08 | 트레테라 코퍼레이션 | 데옥시시티딘 키나제 억제제의 결정형 및 이의 용도 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA200400708A1 (ru) * | 2001-11-22 | 2004-10-28 | Биовитрум Аб | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 |
US7173030B2 (en) * | 2003-05-21 | 2007-02-06 | Biovitrum Ab | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
WO2004103980A1 (fr) * | 2003-05-21 | 2004-12-02 | Biovitrum Ab | Inhibiteurs de 11-beta-hydroxy steroide deshydrogenase de type i |
AU2004255342C1 (en) * | 2003-07-08 | 2009-05-14 | Novartis Ag | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds |
US7507832B2 (en) * | 2003-12-22 | 2009-03-24 | Eli Lilly And Company | Triazole PPAR modulators |
-
2006
- 2006-09-26 WO PCT/EP2006/009297 patent/WO2007039171A1/fr active Application Filing
- 2006-09-26 KR KR1020087008301A patent/KR20080053931A/ko not_active Application Discontinuation
- 2006-09-26 RU RU2008113210/04A patent/RU2008113210A/ru not_active Application Discontinuation
- 2006-09-26 AU AU2006299085A patent/AU2006299085A1/en not_active Abandoned
- 2006-09-26 EP EP06805856A patent/EP1937658A1/fr not_active Withdrawn
- 2006-09-26 CN CNA2006800368676A patent/CN101277940A/zh active Pending
- 2006-09-26 JP JP2008533904A patent/JP2009510144A/ja not_active Abandoned
- 2006-09-26 CA CA002624726A patent/CA2624726A1/fr not_active Abandoned
- 2006-09-27 TW TW095135653A patent/TW200804324A/zh unknown
- 2006-10-04 AR ARP060104361A patent/AR056121A1/es not_active Application Discontinuation
-
2008
- 2008-03-03 ZA ZA200801988A patent/ZA200801988B/xx unknown
- 2008-03-26 IL IL190460A patent/IL190460A0/en unknown
- 2008-03-31 MA MA30788A patent/MA29810B1/fr unknown
- 2008-04-04 US US12/062,769 patent/US7910612B2/en not_active Expired - Fee Related
- 2008-04-04 NO NO20081682A patent/NO20081682L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20090012131A1 (en) | 2009-01-08 |
CA2624726A1 (fr) | 2007-04-12 |
EP1937658A1 (fr) | 2008-07-02 |
WO2007039171A1 (fr) | 2007-04-12 |
ZA200801988B (en) | 2008-12-31 |
AR056121A1 (es) | 2007-09-19 |
NO20081682L (no) | 2008-05-06 |
CN101277940A (zh) | 2008-10-01 |
RU2008113210A (ru) | 2009-10-10 |
AU2006299085A1 (en) | 2007-04-12 |
KR20080053931A (ko) | 2008-06-16 |
US7910612B2 (en) | 2011-03-22 |
IL190460A0 (en) | 2008-11-03 |
JP2009510144A (ja) | 2009-03-12 |
TW200804324A (en) | 2008-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29810B1 (fr) | 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques | |
MA29804B1 (fr) | Derives de phenyl-et pyridyl-1,2,4-oxadiazolone renfermant un groupe phenyle, procedes pour leur preparation et leur utilisation en tant qu'agents pharmaceutiques | |
MA30906B1 (fr) | Composes et compositions en tant quinhibiteurs des proteines kinases | |
Campolo et al. | Multiple mechanisms of dimethyl fumarate in amyloid β‐induced neurotoxicity in human neuronal cells | |
MA30981B1 (fr) | Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments | |
West et al. | Induction of apoptosis in colorectal carcinoma cells treated with 4-hydroxy-2-nonenal and structurally related aldehydic products of lipid peroxidation | |
MA30782B1 (fr) | Amides substitues, procede de production et d'utilisation desdits amides | |
MA29805B1 (fr) | Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques | |
MA31276B1 (fr) | Amides substitués, procédé de production et d'utilisation desdits amides. | |
TN2009000138A1 (fr) | Biaryl-ether-urees | |
MA47447A (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
MA29692B1 (fr) | Derives de la xanthine en tant qu'agonistes selectifs du hm74a | |
MA29812B1 (fr) | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides cycliques, procedes pour leur preparation et leur utilisation en tant que substances pharmaceutiques | |
MA29411B1 (fr) | 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa | |
MA30084B1 (fr) | Triazolopyridazines en tant que modulateurs de la tyrosine kinase | |
MA33450B1 (fr) | Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques | |
IL167694A (en) | Use of quinazulin-4-on derivatives is used to make derivatives and pharmaceutical preparations containing the derivatives | |
MA27097A1 (fr) | Aza-arylpiperazines | |
MA30916B1 (fr) | Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine | |
MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif | |
MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
MA29379B1 (fr) | Derives de pyrrolidine 3,4-substitues pour le traitement de l'hypertension | |
MA27741A1 (fr) | Derives diarylcycloalkyles , procede pour leur production, et leur utilisation en tant que medicaments | |
MA31919B1 (fr) | Composés inhibiteurs de la dipeptidyl peptidase-iv, leurs procédés de préparation, et compositions pharmaceutiques contenant ces composés comme agent actif | |
MA29723B1 (fr) | Composes |